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Abstract
Background: Previous studies have examined the association between ABO blood group and the risk of some malignancies.
However, no prospective cohort study to date has examined the association between ABO blood group and the risk of skin
cancer.
Methodology/Principal Findings: Using two large cohorts in the US, we examined ABO blood type and incidence of skin
cancer, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). We followed up study
participants (70,650 female nurses and 24,820 male health professionals) on their diagnosis of incident skin cancer from
cohort baseline (1976 in women and 1986 in men) until 2006. Study participants reported their blood type in 1996 in both
cohorts. During the follow-up, 685 participants developed melanoma, 1,533 developed SCC and 19,860 developed BCC. We
used Cox proportional hazards models to calculate the hazard ratios (HR) and 95% confidence intervals (CI) of each type of
skin cancer. We observed that non-O blood group (A, AB, and B combined) was significantly associated with a decreased risk
of non-melanoma skin cancer overall. Compared to participants with blood group O, participants with non-O blood group
had a 14% decreased risk of developing SCC (multivariable HR: 0.86; 95% CI: 0.78, 0.95) and a 4% decreased risk of
developing BCC (multivariable HR: 0.96; 95% CI: 0.93, 0.99). The decreased risk of melanoma for non-O blood group was not
statistically significant (multivariable HR: 0.91; 95% CI: 0.78, 1.05).
Conclusion/Significance: In two large independent populations, non-O blood group was associated with a decreased risk
of skin cancer. The association was statistically significant for non-melanoma skin cancer. Additional studies are needed to
confirm these associations and to define the mechanisms by which ABO blood type or closely linked genetic variants may
influence skin cancer risk.
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Introduction
Skin cancer is the most common malignancy and represents
approximately half of all cancers in the United States. Each year
more than 1 million cases of skin cancer are diagnosed in this
country. There were about 11,590 deaths from skin cancer in 2009
[1]. Risk factors of skin cancer include ultraviolet light exposure,
age, male gender, genetic susceptibility, and constitutional factors,
for instance hair color, number of moles, skin color, and skin
reaction to sun exposures [1–5]. There are three types of skin
cancer: melanoma, squamous cell carcinoma (SCC), and basal cell
carcinoma (BCC) originating from three major types of cells in the
epidermis.
ABO blood groups are defined by carbohydrate moieties on the
extracellular surface of the red blood cell membranes. Red blood
cell antigens have various functions, including membrane
structural integrity, transportation of molecules through mem-
branes, and adhesion [6]. Along with their expression on red blood
cells, ABO antigens are also highly expressed on the surface of
epithelial cells. Previous studies suggest a possible association
between ABO blood group and the risk of some epithelial
malignancies, including pancreatic cancer [7] and gastric cancer
[8]. Several plausible mechanisms, including inflammation,
immune-surveillance for malignant cells, intercellular adhesion,
and membrane signaling have been proposed to explain the
observed association between ABO blood groups and cancer risk
[7].
The purpose of this study was to examine possible associations
between ABO blood group and the risk of various types of skin
cancer in two large national cohorts.
Materials and Methods
Ethics Statement
This study was approved by the Human Research Committee
at the Brigham and Women’s Hospital (Boston, MA) with written
informed consent from all participants.
Study population
The Nurses’ Health Study (NHS) began in 1976, when 121,700
registered nurses aged 30–50 years in 11 US states completed a
baseline questionnaire regarding risk factors for cancer and
cardiovascular diseases. Participants completed self-administered,
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e11972mailed follow-up questionnaires biennially with updated informa-
tion on their lifestyle, medical history, and diet. The Health
Professionals Follow-up Study (HPFS) began in 1986 when 51,529
US male health professionals, including dentists, veterinarians,
pharmacists, and optometrists, aged 40–75 years, completed a
baseline questionnaire on lifestyle, diet, and medical conditions.
The information was updated biennially with follow-up question-
naires.
Assessment of ABO blood group and skin cancer risk
factors
In 1996, questions on ABO blood group were included in the
questionnaires. Participants in both the NHS and HPFS cohorts
were asked about their blood type (A, B, AB, O, or unknown).
Though not all ABO blood type results were confirmed
serologically, we did obtain laboratory confirmation of the self-
reported blood type in a subsample of 98 participants for
validation. The overall concordance rate was 91% between the
self-reported results and the serologically confirmed results. This
rate of validation of ABO blood group did not differ between the
two cohorts: the concordance rate was 93% for NHS and 90% for
HPFS [7]. For skin cancer risk factors, data were obtained from
follow-up questionnaires in both cohorts. They included sunburn
reaction, family history of melanoma, number of severe sunburns,
number of moles, hair color, sun exposure, and residence at
different ages.
Identification of skin cancer cases
Skin cancer identification was performed routinely in both
cohorts. Participants reported new diagnosis biennially. With their
permission, participants’ medical records were obtained and
reviewed by physicians to confirm their self-reported diagnosis.
Only pathologically confirmed invasive cases of melanoma and
SCC were included in this study. Medical records were not
obtained for self-reported cases of BCC, and the validity of BCC
self-reports was $90% in our study [9,10].
Statistical analyses
Participants who did not report their blood type in the 1996
questionnaire were excluded from analyses (44,287 in NHS and
21,360 in HPFS). Non-whites were excluded due to insufficient
sample sizes in each race category for analyses. Also excluded were
participants who had cancer, including skin cancer, before
baseline in both cohorts (1976 in the NHS and 1986 in the
HPFS). The primary exposure was the participants’ self-reported
ABO blood type, assessed in 1996. Participants contributed
person-time from the baseline. Accumulation of follow-up time
ceased at the first report of BCC, the first report followed by
confirmation of SCC, the first report followed by confirmation of
melanoma, death from another cause, or the end of follow-up
(NHS by June 2006; HPFS by January 2006), whichever came
earlier. We used Cox proportional hazards models to calculate the
hazard ratios (HRs) and 95% confidence intervals (CIs) of each
type of skin cancer. We tested the assumption of Proportional
Hazards. The tests were not statistically significant (p=0.34 for
melanoma, p=0.25 for SCC, and p=0.79 for BCC). In the
multivariate analysis, we simultaneously controlled for the above-
mentioned skin cancer risk factors. In the combined analysis of the
two cohorts, we additionally controlled for gender.
Results
There were 70,650 female nurses and 24,820 male health
professionals included in the analysis. The mean follow-up time
was 27.1 years for women and 16.9 years for men. The
characteristics of participants in our study were similar across
ABO blood groups (Table 1). The frequency distribution of ABO
blood groups in the NHS and HPFS were similar (Table 2).
Between baseline and 2006, 685 participants developed
melanoma, 1,533 participants developed SCC, and 19,860
participants developed BCC. Compared to participants with
blood group O, the risk of developing SCC was significantly lower
for participants in blood group A (multivariable HR: 0.86; 95%
CI: 0.77, 0.96). We did not observe a significantly lower risk of
developing SCC for participants with blood group AB and B
(multivariable HR: 0.83; 95% CI: 0.67, 1.01 and multivariable
HR: 0.88; 95% CI: 0.75, 1.04) compared to participants with
blood group O. Overall, the risk of developing SCC was
significantly lower for participants with non-O blood group (A,
AB, and B combined) (multivariable HR: 0.86; 95% CI: 0.78,
0.95) compared to participants with blood group O. The slightly
decreased risk of developing BCC was similar across blood groups
Table 1. Characteristics of the Nurses’ Health Study and
Health Professional Follow-Up Study combined by ABO blood
type (1996).
Blood group
Characteristics O A AB B
No. of subjects
NHS 30,298 25,455 5,529 9,368
HPFS 10,609 9,397 1,843 2,971
Total 40,907 34,852 7,372 12,339
Mean age, years 62.3 62.2 63.5 62.1
Female, % 74.1 73.0 75.5 75.7
Red or Blond hair, % 15.5 15.4 14.8 14.7
Adolescent sunburn reaction, % 46.8 45.4 44.3 44.6
Number of severe sunburns 6+, % 48.3 47.8 46.2 47.1
Number of moles on arms 3+, % 13.1 13.0 12.6 12.5
Family history of melanoma, % 2.9 3.0 3.4 3.1
College/high school sun exposure
$11 hrs/week, %
23.2 23.6 21.9 22.0
Age 25–35$11 hrs/week, % 18.2 18.0 17.4 16.6
Age 36–59$11 hrs/week, % 14.5 14.0 14.5 13.2
Age 60$11 hrs/week, % 12.6 12.8 12.8 11.2
doi:10.1371/journal.pone.0011972.t001
Table 2. Distribution of ABO blood group and Rh type
among subjects from NHS, HPFS, and two cohorts combined.
Blood group NHS (%) HPFS (%) Total study population (%)
O 42.9 42.7 42.8
A 36.0 37.9 36.5
AB 7.8 7.4 7.7
B 13.3 12.0 12.9
Rh negative 22.6 21.4 22.3
Rh positive 77.4 78.6 77.7
NHS=Nurses’ Health Study, HPFS=Health Professionals Follow-up Study.
doi:10.1371/journal.pone.0011972.t002
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The multivariable HR of BCC was 0.96 (95% CI: 0.93, 0.99) for
non-O blood group (A, AB, and B combined) compared to
participants with blood group O. We did not observe a statistically
significant decreased risk of developing melanoma across blood
groups of A, AB, and B, compared to participants with blood
group O. The multivariable HR of melanoma for non-O blood
group (A, AB, and B combined) was 0.91 (95% CI: 0.78, 1.05).
The HRs of each type of skin cancer did not change materially
after multivariable adjustment for other risk factors of skin cancer.
Kaplan-Meier Curves of melanoma, SCC, and BCC were shown
in Figure 1. There was no association between the Rh factor and
the risk of any type of skin cancer (Table 3).
In addition, we performed a secondary analysis using the ABO
blood group assessment date (1996) as the baseline of the follow-up.
With 571 SCC cases in total, we confirmed this result: the HR of
SCC for participants with blood group A was 0.83 (95% CI: 0.71,
0.95) in the two cohorts combined. For participants with blood
group AB and B, the HRs of SCC were 0.85 (95% CI: 0.65, 1.10)
and 0.92 (95% CI: 0.75, 1.13) compared to participants with blood
group O. No statistically significant associations were observed
between any blood group and the risks of melanoma and BCC.
Discussion
Our results suggest that non-O blood group was significantly
associated with a decreased risk of non-melanoma skin cancer
overall. Compared to participants with blood group O, partici-
pants with non-O blood group had a 14% decreased risk of
developing SCC and a 4% decreased risk of developing BCC. The
decreased risk of melanoma for non-O blood group (A, AB, and B
combined or separately) was not statistically significant.
There are several plausible hypotheses for the observed
association between ABO blood groups and skin cancer risk.
One possible explanation is that ABO blood group may be directly
associated with skin cancer through certain biological mechanisms.
Blood group antigens are expressed on the surface of many
epithelial cells, including skin cells [11]. One study evaluating
normal penile skin compared to squamous cell carcinoma showed
less A antigen expression in SCC compared to normal skin [12],
which is consistent with our finding that A blood type was less
common in SCC cases. Other studies have shown that ABO blood
group antigen expression in tumors is associated with metastasis
and prognosis [8,13,14,15]. Hence, several plausible mechanisms,
including inflammation, immunosurveillance for malignant cells,
Table 3. Age-adjusted
1 and multivariable-adjusted
2 hazard ratios and 95% confidence intervals for skin cancers by ABO blood
type.
ABO blood type
Chracteristics O A AB B A, AB, B combined
Melanoma
NHS
1 1.00 (ref.) 0.86 (0.70–1.05) 0.84 (0.59–1.19) 0.80 (0.59–1.07) 0.84 (0.70–1.00)
NHS
2 1.00 (ref.) 0.88 (0.72–1.07) 0.87 (0.61–1.24) 0.80 (0.60–1.08) 0.86 (0.72–1.03)
HPFS
1 1.00 (ref.) 1.02 (0.75–1.39) 0.85 (0.47–1.53) 1.07 (0.69–1.66) 1.01 (0.77–1.34)
HPFS
2 1.00 (ref.) 1.04 (0.76–1.42) 0.94 (0.52–1.69) 1.12 (0.72–1.75) 1.04 (0.79–1.38)
Combined
1,3 1.00 (ref.) 0.91 (0.77–1.07) 0.83 (0.61–1.12) 0.87 (0.68–1.11) 0.89 (0.76–1.03)
Combined
2,3 1.00 (ref.) 0.92 (0.78–1.09) 0.88 (0.65–1.19) 0.89 (0.70–1.13) 0.91 (0.78–1.05)
Combined
3 No. of cases
4 313 242 48 82 372
Squamous Cell Carcinoma
NHS
1 1.00 (ref.) 0.85 (0.74–0.99) 0.80 (0.62–1.04) 0.84 (0.68–1.03) 0.84 (0.74–0.96)
NHS
2 1.00 (ref.) 0.87 (0.75–1.01) 0.86 (0.66–1.11) 0.86 (0.70–1.06) 0.87 (0.76–0.99)
HPFS
1 1.00 (ref.) 0.84 (0.70–1.00) 0.70 (0.50–0.99) 0.91 (0.70–1.18) 0.84 (0.71–0.98)
HPFS
2 1.00 (ref.) 0.85 (0.71–1.02) 0.78 (0.55–1.09) 0.93 (0.72–1.21) 0.86 (0.74–1.01)
Combined
1,3 1.00 (ref.) 0.86 (0.77–0.96) 0.75 (0.61–0.92) 0.86 (0.73–1.01) 0.84 (0.76–0.93)
Combined
2,3 1.00 (ref.) 0.86 (0.77–0.96) 0.83 (0.67–1.01) 0.88 (0.75–1.04) 0.86 (0.78–0.95)
Combined
3 No. of cases
4 720 525 104 184 813
Basal Cell Carcinoma
NHS
1 1.00 (ref.) 0.94 (0.90–0.97) 0.90 (0.84–0.96) 0.92 (0.87–0.97) 0.93 (0.90–0.96)
NHS
2 1.00 (ref.) 0.95 (0.92–0.99) 0.94 (0.88–1.00) 0.92 (0.87–0.96) 0.94 (0.91–0.97)
HPFS
1 1.00 (ref.) 0.97 (0.92–1.03) 0.99 (0.89–1.10) 1.00 (0.91–1.09) 0.98 (0.93–1.03)
HPFS
2 1.00 (ref.) 0.99 (0.93–1.05) 1.09 (0.98–1.21) 1.04 (0.95–1.13) 1.01 (0.96–1.07)
Combined
1,3 1.00 (ref.) 0.95 (0.92–0.98) 0.91 (0.87–0.97) 0.94 (0.89–0.98) 0.94 (0.92–0.97)
Combined
2,3 1.00 (ref.) 0.96 (0.93–0.99) 0.97 (0.92–1.03) 0.95 (0.90–0.99) 0.96 (0.93–0.99)
Combined
3 No. of cases
4 8,758 7,106 1,526 2,470 11,102
1Age-adjusted.
2Multivariate-adjusted for sunburn reaction, family history of melanoma, number of severe sunburns, number of moles, hair color, sun exposure, and residence at
different ages.
3The combined analysis of the two cohorts additionally adjusted for gender.
4Number of person-years: 995,274, 850,292, 180,025, and 305,206 for O, A, AB, and B blood types, respectively.
doi:10.1371/journal.pone.0011972.t003
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proposed to explain the observed association between ABO blood
groups and cancer risk [7]. In addition, the ABO gene on
chromosome 9q34 encodes glycotransferases to form the ABO
blood group antigens [16]. Differential expression of blood group
antigens on epithelial cells may influence tumorigenesis through
altered glycosyltransferase specificity [7]. An alternative explana-
tion is that ABO blood group may be indirectly associated with
skin cancer. It is possible that the ABO gene was in linkage
disequilibrium with other genes involved in skin carcinogenesis.
Many previous studies have reported an association between
ABO blood group and the risk of various cancers, especially
epithelial cancers. One study using the same two cohorts reported
an association between ABO blood type and the risk of developing
pancreatic cancer (P=.004; log-rank test). In this study, compared
with participants with blood group O, those with blood groups A,
AB, or B were more likely to develop pancreatic cancer (adjusted
HRs for incident pancreatic cancer were1.32, 1.51, and 1.72,
respectively) [7]. Another NHS-based study suggested the
presence of the B antigen was positively associated with the risk
of epithelial ovarian cancer, while blood group A was not
associated with risk (manuscript in submission).
To date, ours is the first prospective cohort study investigating
the relationship between ABO blood group and the risk of skin
cancers. Only one previous case-control study conducted in
Turkey examined the relationship between ABO blood groups and
skin cancers [17]. The study recruited 98 histologically confirmed
skin cancer cases (23 SCC, 42 BCC, and 33 in situ SCC) and 419
healthy controls. Skin cancer cases were more likely than controls
to be in blood groups A, AB, and B than O (odds ratios ranged
from 1.50 to 3.77), but these results were not statistically
significant. There are several possible reasons for the observed
differences between our results and the results of the previous case-
control study. First, our participants are white residing in the US,
while the case-control study population was from Mersin in
Turkey. The association between ABO blood group and the risk of
skin cancer may vary among different races or ethnicities. Second,
results from the previous case-control study were based on a
relatively small sample size, and confidence intervals were wide.
One of the major strengths of our study is its prospective design.
We performed a secondary analysis using the ABO blood group
assessment data (1996) as the baseline for the follow-up to confirm
our primary analysis results. Another strength of our study is the
large study population and the high follow-up rate. Also, the
availability of many risk factor covariates allowed us to assess the
association while controlling for potential confounding within each
ABO blood group. The high concordance rate between reported
blood type and serologic testing in a subset of our study population
suggests the validity of self-reported blood type.
In conclusion, data from two large cohort studies demonstrated
the association between non-O blood group and a decreased risk
of each type of skin cancer. The association was statistically
significant for non-melanoma skin cancer. The opposing associ-
ation of the non-O blood group with skin cancer compared to that
with pancreatic, gastric, and ovarian cancers suggests unique
carcinogenic mechanisms of skin cancer. We considered the
analysis exploratory and further investigation is warranted to
confirm this finding and to illuminate skin carcinogenesis.
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